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Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results
in substantial interobserver concordance
Aims: Robust prognostic markers for ductal carci-
noma in situ (DCIS) of the breast require high
reproducibility and thus low interobserver variabil-
ity. The aim of this study was to compare interob-
server variability among 13 pathologists, in order
to enable the identification of robust histopathologi-
cal characteristics.
Methods and results: One representative haema-
toxylin and eosin-stained slide was selected for 153
DCIS cases. All pathologists independently assessed
nuclear grade, intraductal calcifications, necrosis,
solid growth, stromal changes, stromal inflamma-
tion, and apocrine differentiation. All characteristics
were assessed categorically. Krippendorff’s alpha
was calculated to assess overall interobserver con-
cordance. Cohen’s kappa was calculated for every
observer duo to further explore interobserver vari-
ability. The highest concordance was observed for
necrosis, calcifications, and stromal inflammation.
Assessment of solid growth, nuclear grade and stro-
mal changes resulted in lower concordance. Poor
concordance was observed for apocrine differentia-
tion. Kappa values for each observer duo identified
the ‘ideal’ cut-off for dichotomisation of multicate-
gory variables. For instance, concordance was
higher for ‘non-high versus high’ nuclear grade
than for ‘low versus non-low’ nuclear grade.
‘Absent/mild’ versus ‘moderate/extensive’ stromal
inflammation resulted in substantially higher con-
cordance than other dichotomous cut-offs.
Conclusions: Dichotomous assessment of the
histopathological features of DCIS resulted in moderate
to substantial agreement among pathologists. Future
studies on prognostic markers in DCIS should take into
account this degree of interobserver variability to
define cut-offs for categorically assessed histopathologi-
cal features, as reproducibility is paramount for robust
prognostic markers in daily clinical practice. A new
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prognostic index for DCIS might be considered, based
on two-tier grading of histopathological features.
Future research should explore the prognostic potential
of such two-tier assessment.
Keywords: ductal carcinoma in situ, interobserver variability, interrater concordance, nuclear grade,
reproducibility, stromal inflammation
Introduction
Ductal carcinoma in situ (DCIS) of the breast repre-
sents a heterogeneous group of non-obligate preinva-
sive precursors of invasive carcinoma of no special
type. The ability of DCIS to progress towards invasive
cancer is likely to result from a complex interplay
between intrinsic and extrinsic factors, such as
genetic anomalies within the neoplastic cells, stromal
remodelling, and stroma-derived proinvasive sig-
nalling.1 Although DCIS has been the subject of
intensive research during the past four decades, no
robust prognostic markers have emerged that enable
prediction of progression towards invasive cancer.
Because surgery has always been the cornerstone of
DCIS treatment, the natural biology of DCIS is poorly
understood. Ongoing clinical trials such as the
COMET, LORD and LORIS trials, which are investigat-
ing watchful waiting strategies for low-grade DCIS,
might provide crucial information to fill this gap in
our knowledge.2–4 The main motive for such trials is
the increasing awareness that significant numbers of
DCIS patients are currently overtreated, as not all
DCIS cases will become invasive.1,5
If these trials can prove that watchful waiting is
not inferior to standard surgical treatment in a
selected subgroup of patients, the search for proper
prognostic markers is likely to be intensified. If DCIS
is left untreated, adequate prognosticators are neces-
sary to estimate the risk of upstaging of DCIS to inva-
sive cancer on the initial biopsy, and to evaluate the
risk of evolution towards invasion in the future. In
addition, these prognosticators could be used to esti-
mate the recurrence risk in patients treated with
lumpectomy, thereby providing information on the
need for additional radiotherapy. Ideally, adequate
prognostic markers should enable us to reduce the
number of patients who undergo surgery, as well as
the number of patients who receive adjuvant irradia-
tion and hormonal therapy. The current uncertainty
about what constitutes ‘high-risk DCIS’ causes signifi-
cant variability in treatment.5 In the past, several
histopathological and immunohistochemical charac-
teristics of DCIS have been investigated, often with
conflicting results regarding their potential for recur-
rence risk prediction. We wondered whether
interobserver variability might explain such conflict-
ing results. Adequate prognostic markers require
robustness of assessment, i.e. high reproducibility and
thus low interobserver variability.
The goal of this study was to investigate the levels of
interobserver variability among histopathologists in
the assessment of DCIS. Investigation of interrater con-
cordance should enable the identification of repro-
ducible robust histopathological features. In addition,
this study could compel us to develop new definitions
or cut-offs for those characteristics with poor interrater
concordance, to enhance the robustness of assessment
in the daily routine of histopathology laboratories.
Materials and methods
P A T I E N T S
All patients were women who consecutively under-
went breast-conserving surgery or mastectomy for
DCIS between 1 January 2007 and 31 December
2015 at Ghent University Hospital (Ghent, Belgium).
Needle biopsies or vacuum-assisted core biopsies were
excluded. DCIS cases with associated microinvasive
foci were included, but DCIS cases admixed with
invasive carcinoma (size of >1 mm) were excluded.
All haematoxylin and eosin-stained slides were
retrieved from the archives of the Department of
Pathology (Ghent University Hospital), and reviewed
by one pathologist (M.V.B.). One representative glass
slide was selected for each lesion, and this single slide
was used for subsequent histopathological assess-
ment. No consecutive sections were cut from the cor-
responding tissue blocks. All pathologists (coded P1–
P13) assessed the selected slides independently by
using a light microscope. No digitally scanned slides
were used. All ‘observers’ are routinely involved in
breast pathology in academic and non-academic hos-
pitals. This study was approved by the ethics commit-
tee of Ghent University Hospital (EC/2018/0014).
D E F I N I T I O N S F O R C A T E G O R I C A L A S S E S S M E N T
All histopathological features were assessed categorically.
All participants were provided with detailed guidelines
regarding the variables within each category. No training
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set was used, as this study concerned commonly assessed
features. Nuclear grade was assessed as a three-tier variable
according to the American Society of Clinical Oncology/Col-
lege of American Pathologists protocol for examination of
DCIS specimens,6 which is partly based on the 1997 Con-
sensus Conference on DCIS classification.7 Nuclear grade
was categorised as low, intermediate, or high, on the basis
of nuclear size, pleomorphism, chromatin distribution,
nucleoli, mitoses, and orientation of nuclei.6,7
Ductal carcinoma in situ architecture included solid,
cribriform, papillary and micropapillary growth,
regardless of comedonecrosis,8,9 and was assessed
dichotomously: predominantly solid and non-solid
architectures were defined as ≥50% and <50% solid
growth, respectively. Necrosis was classified into four
categories.6,9 Necrosis was defined as areas of conflu-
ent eosinophilic material containing ghost cells and
karyorrhectic debris, and categorised as follows: no
necrosis, single-cell necrosis, focal necrosis (necrotic
debris in <50% of affected ducts), and extensive necro-
sis (necrotic debris in ≥50% of affected ducts).9 Calcifi-
cations within DCIS were scored as present or absent.
Periductal stromal changes were classified semi-
quantitatively as previously described.10 Myxoid
stroma was defined as loosely arranged collagen fibres,
interspersed with an amorphous, slightly basophilic
substance (illustrated in Van Bockstal et al.10–12 and
Figure 1A,B). Periductal stromal changes were divided
into four categories. DCIS showed either periductal
sclerotic stroma without (<1% of ducts) myxoid
changes, a mild amount (i.e. ≥1% but <33% of ducts)
of myxoid stroma, a moderate amount (i.e. ≥33% but
<66% of ducts) of myxoid stroma, or an extensive
amount (i.e. ≥66% of ducts) myxoid stroma.
The presence and degree of a chronic inflammatory
infiltrate in the periductal stroma were recorded semi-
quantitatively as previously described.9,10,13,14 Four
categories were discerned. In DCIS with ‘no stromal
inflammation’ (Figure 2A), the periductal stroma was
not infiltrated by lymphocytes. In DCIS with ‘mild
stromal inflammation’ (Figure 2B), the periductal
stroma surrounding the affected ducts was infiltrated
by a few loosely arranged lymphocytes but dense
lymphocytic aggregates were absent, so the periductal
stroma was easy to perceive. In DCIS with ‘moderate
stromal inflammation’ (Figure 2C), the majority (i.e.
≥50%) of the ducts were surrounded by a moderately
dense inflammatory infiltrate: lymphoid aggregates
were present but lymphoid follicle formation was
absent, and assessment of the periductal stroma was
not hampered by the density of the infiltrate. In DCIS
with ‘extensive stromal inflammation’ (Figure 2D),
the majority (i.e. ≥50%) of the ducts were surrounded
by a dense inflammatory infiltrate, consisting of large
aggregates of lymphocytes. The density of this infil-
trate hampered assessment of the periductal stroma.
Lymphoid follicle formation could be present, but was
not a prerequisite.
Apocrine differentiation was defined as previously
described,15 and was assessed regardless of the
growth pattern. DCIS was classified as apocrine when
>50% of the lesion showed apocrine features, i.e.
abundant eosinophilic cytoplasm and large pleomor-
phic vesicular nuclei with prominent nucleoli.15 No
additional immunohistochemistry was used to deter-
mine apocrine differentiation.
S T A T I S T I C S
Statistical analyses were performed with IBM SPSS
STATISTICS 25.0 (IBM, Chicago, IL, USA). The arith-
metic mean was calculated for each DCIS lesion and
A
B
Figure 1. Photomicrographs of haematoxylin and eosin staining
illustrating ductal carcinoma in situ (DCIS) with predominantly
sclerotic periductal stroma (A), and DCIS with predominantly myx-
oid periductal stroma (B).
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for each histopathological feature, to assess the distri-
bution of each feature within this cohort of DCIS
cases. This average score accords with the most com-
monly addressed category for a specific feature for
each lesion. For calculation of Krippendorff’s alpha
(KA) reliability estimates, the ‘Kalpha’ macro pro-
vided by Hayes and Krippendorff was used (http://af
hayes.com/spss-sas-and-mplus-macros-and-code.
html). This macro computes KA for categorical data,
regardless of the number of observers and categories,
and regardless of any missing data.16,17 KA (with the
number of bootstrap samples set at 10 000) was used
to investigate overall interrater concordance for each
feature. Cohen’s kappa values were calculated for
each observer duo (i.e. 78 kappa values for each
dichotomised histopathological feature), as this
allowed detailed investigation of differences in recipro-
cal interrater concordance. Box-and-whisker plots
were constructed in SPSS to visualise distributions of
Cohen’s kappa for each dichotomised feature. Inter-
pretation was performed according to Landis and
Koch.18 Spearman’s rho was determined to investi-
gate possible correlations between the degree of con-
cordance among pathologists and their relative
experience, i.e. the number of years in practice.
Results
P E R C E N T A G E A G R E E M E N T
All histopathological features were classified in two,
three or four categories by 13 observers. The partici-
pating pathologists had been in practice for 14 years
on average (range 3–31 years). No significant corre-
lation was observed between number of years in
practice and degree of interobserver concordance
(Spearman’s rho ranging from 0.142 to 0.059;
P > 0.05), although this might have been due to the
limited number of participants. All observers rated all
cases (n = 153). There were four missing values in
the dataset. The distribution of all histopathological
features is shown in Figure 3, based on the average
scores provided by all observers. Percentage agree-
ment signifies the number of cases that were rated
identically by all pathologists. Twenty-seven of 153
DCIS cases (17.6%) received an identical nuclear
A
B
C
D
Figure 2. Photomicrographs of haematoxylin and eosin staining
illustrating ductal carcinoma in situ with no periductal stromal
inflammation (A), mild periductal stromal inflammation (B), moder-
ate periductal stromal inflammation (C), and extensive periductal
stromal inflammation (D).
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grade, and these were all considered to be high-grade.
Fifty-five of 153 DCIS cases (36.0%) were rated iden-
tically for solid growth pattern. Intraductal calcifica-
tions were assessed identically in 72 of 153 DCIS
cases (47.1%). Ten of 153 DCIS cases (6.5%) received
identical scores for necrosis. Periductal stromal
changes were rated identically in six of 153 DCIS
cases (3.9%). No DCIS cases (0%) were rated similarly
for stromal inflammation. All pathologists agreed that
apocrine differentiation was lacking in 79 of 153
DCIS cases (51.6%), but disagreement existed for the
other 74 cases (48.4%).
O V E R A L L I N T E R O B S E R V E R C O N C O R D A N C E
Krippendorff’s alpha was highest for necrosis
[0.6885, 95% confidence interval (CI) 0.6315–
0.7413], calcifications (0.6456, 95% CI 0.5356–
0.7476), and stromal inflammation (0.6355, 95% CI
0.5807–0.6863). KA was lower for solid growth pat-
tern (0.5935, 95% CI 0.4985–0.6815), nuclear
grade (0.5629, 95% CI 0.4688–0.6523), and
periductal stromal changes (0.4463, 95% CI 0.3635–
0.5264). KA was very low for apocrine differentiation
(0.2819, 95% CI 0.0841 to 0.5870), indicating
poor concordance.
C O M P A R I S O N O F P A T H O L O G I S T D U O S
Krippendorff’s alpha does not allow detailed analysis
of interobserver variability among different partici-
pants. Therefore, Cohen’s kappa was calculated for
each pathologist duo, which required 78 calculations
for each histopathological feature (Tables 1, 2 and
Tables S1–S12). All categorical variables were dichot-
omised with all possible cut-offs to enable comparison
of the kappa distributions for each feature. The ‘ideal’
cut-off (i.e. the cut-off with the highest median inter-
rater concordance and the most narrow distribution)
was identified. No particular patterns of scoring by
the participants were observed: no differences were
noted between those with greater or fewer years in
practice, or between those within the same practice.
Nuclear grade was dichotomised in two ways: first,
intermediate grade was combined with low grade to
form a ‘non-high-grade’ group; and second, interme-
diate grade was combined with high grade to form a
‘non-low-grade’ group. Non-high-grade versus high-
grade dichotomisation resulted in higher concordance
(median kappa of 0.526) and a narrower range than
low-grade versus non-low-grade dichotomisation (me-
dian kappa of 0.394; Figure 4). Assessment of solid
DCIS growth and the presence of calcifications
resulted in median kappa values of 0.600 and 0.648,
respectively, and both histopathological features
showed narrow distributions of kappa values
(Figure 4).
The four necrosis categories were dichotomised
according to three different cut-offs: no necrosis ver-
sus any necrosis with a median kappa of 0.417; no
necrosis or single-cell necrosis versus focal or exten-
sive necrosis with a median kappa of 0.627; and
non-extensive necrosis versus extensive necrosis with
a median kappa of 0.587. The first and the last of
Nuclear grade
Stromal inflammation Myxoid stroma Calcifications
Necrosis DCIS growth pattern Apocrine DCIS
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Figure 3. Pie charts illustrating the distribution of six histopathological features throughout the ductal carcinoma in situ (DCIS) cohort
(n = 153). All features were assessed by 13 pathologists, and the average score was calculated for nuclear grade (A), necrosis (B), predomi-
nantly solid or predominantly non-solid DCIS growth pattern (C), apocrine differentiation (D), periductal stromal inflammation (E), myxoid
periductal stromal changes (F), and the presence or absence of intraductal calcifications (G).
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these dichotomisations resulted in a substantially
broader kappa distribution than dichotomisation as
no or single-cell necrosis versus focal or extensive
necrosis. Assessment of apocrine differentiation
resulted in low concordance (median kappa of
0.277).
Table 2. Cohen’s kappa values for each duo of pathologists, assessing nuclear grade as a two-tier feature, i.e. low nuclear
grade versus non-low nuclear grade
P1
P2 0.434
P3 0.505 0.316
P4 0.393 0.315 0.386
P5 0.416 0.376 0.443 0.632
P6 0.398 0.335 0.329 0.464 0.414
P7 0.247 0.286 0.383 0.243 0.261 0.152
P8 0.315 0.147 0.243 0.422 0.514 0.541 0.136
P9 0.341 0.316 0.401 0.497 0.443 0.329 0.589 0.243
P10 0.645 0.414 0.303 0.529 0.405 0.446 0.184 0.311 0.396
P11 0.394 0.233 0.211 0.458 0.579 0.477 0.203 0.479 0.355 0.444
P12 0.208 0.037 0.316 0.511 0.532 0.279 0.286 0.405 0.565 0.331 0.500
P13 0.542 0.373 0.302 0.396 0.560 0.461 0.171 0.462 0.366 0.491 0.522 0.373
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13
Table 1. Cohen’s kappa values for each duo of pathologists, assessing nuclear grade as a two-tier feature, i.e. non-high
nuclear grade versus high nuclear grade
P1
P2 0.545
P3 0.557 0.583
P4 0.674 0.465 0.542
P5 0.539 0.537 0.607 0.568
P6 0.503 0.501 0.593 0.477 0.613
P7 0.459 0.410 0.430 0.388 0.360 0.336
P8 0.543 0.489 0.554 0.490 0.653 0.637 0.352
P9 0.480 0.403 0.380 0.362 0.293 0.320 0.741 0.312
P10 0.513 0.619 0.621 0.530 0.571 0.585 0.478 0.572 0.396
P11 0.578 0.473 0.634 0.543 0.585 0.547 0.515 0.586 0.432 0.541
P12 0.618 0.566 0.673 0.530 0.571 0.507 0.532 0.572 0.423 0.633 0.594
P13 0.429 0.478 0.462 0.581 0.505 0.487 0.296 0.500 0.282 0.482 0.522 0.430
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13
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The four categories of periductal stromal change
were dichotomised according to three different cut-
offs of 1%, 33% and 66% of ducts surrounded by
myxoid periductal stroma, resulting in median kappa
values of 0.368, 0.378, and 0.333, respectively. Simi-
larly, stromal inflammation was dichotomised accord-
ing to three different cut-offs: absent inflammation
versus any inflammation with a median kappa of
0.235; absent or mild inflammation versus moderate
to extensive inflammation with a median kappa of
0.579; and non-extensive inflammation versus exten-
sive inflammation with a median kappa of 0.566
(Figure 4).
Discussion
Before the prognostic potential of a particular trait is
investigated, the reproducibility of assessment should
be examined. If a characteristic is deemed to be signifi-
cantly associated with prognosis, its assessment should
not be prone to high interobserver variability. As stud-
ies on prognostic markers in DCIS have often reported
conflicting evidence, we wondered whether the differ-
ent results might be due to substantial interobserver
discordance. Therefore, we investigated interobserver
variability among a group of 13 pathologists.
Percentage agreement among all observers was
generally poor, varying from 0% for stromal inflam-
mation to 51.6% for apocrine differentiation. Percent-
age agreement is a weak reliability measure, as it
gives only approximate estimates of interobserver
agreement without taking into account agreement
due to chance. It is extremely influenced by the num-
ber of categories and the prevalence of a particular
trait, which explains why percentage agreement was
lower for features that were not assessed dichoto-
mously, such as periductal stromal changes and
necrosis. Apocrine differentiation was uncommon in
this cohort, and was assessed dichotomously, which
resulted in higher percentage agreement. Multicate-
gorically assessed features with a more regular distri-
bution (such as stromal inflammation and necrosis)
automatically have lower percentage agreement. To
overcome the weaknesses of percentage agreement,
additional reliability measures were determined.
Krippendorff’s alpha was selected as an overall reli-
ability estimate, as it is used for analyses of subjective
judgements, regardless of the number of raters, the
number of rated cases, and the presence of missing
data.16 In the social sciences, a cut-off of KA ≥ 0.800
is generally required for data to be considered to be
reliable.19 Data are considered to be unreliable when
KA is <0.667. With 0.800 > KA ≥ 0.667, it is
1.000
0.900
0.800
0.700
Co
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n’s
 K
ap
pa 0.600
0.500
0.400
0.300
0.200
0.100
0.000
–0.100
1 2 3 4 5 6 7
Histopathological feature
8 9 10 11 12 13 14
Figure 4. Box-and-whisker plots illustrating the distribution of Cohen’s kappa values (y-axis) for each dichotomised histopathological feature
(x-axis). The following histopathological features were assessed as two-tier variables: non-high nuclear grade versus high nuclear grade (1),
low nuclear grade versus non-low nuclear grade (2), non-solid ductal carcinoma in situ (DCIS) growth pattern versus solid DCIS growth pat-
tern (3), presence or absence of intraductal calcifications (4), no necrosis versus any necrosis (5), no or single-cell necrosis versus focal or
extensive necrosis (6), non-extensive necrosis versus extensive necrosis (7), absence or presence of apocrine differentiation (8), <1% periduc-
tal myxoid stroma versus ≥1% periductal myxoid stroma (9), <33% periductal myxoid stroma versus ≥33% periductal myxoid stroma (10),
<66% periductal myxoid stroma versus ≥66% periductal myxoid stroma (11), no stromal inflammation versus any stromal inflammation
(12), no or mild stromal inflammation versus moderate or extensive stromal inflammation (13), and non-extensive stromal inflammation
versus extensive stromal inflammation (14).
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advised to draw only tentative conclusions.19 In that
respect, histopathological assessment would be con-
sidered to be unreliable, as KAs for all but one feature
were <0.667. We would like to emphasise that such
cut-offs are chosen arbitrarily. Interestingly, disagree-
ment itself can provide valuable prognostic informa-
tion, as discordant nuclear grades were shown to
predict outcome in invasive breast cancer.20,21
Although KA is the correct reliability measure for
categorical data assessed by multiple observers, it
does not allow for investigation of mutual relation-
ships among pathologists. Therefore, Cohen’s kappa
was calculated for all observer duos, and this resulted
in 78 kappa values for each dichotomised feature.
Degrees of reliability were compared between all fea-
tures and their applied cut-offs.
So far, (dis)agreement on nuclear grade has been
most intensively studied, and reported kappa values
were generally low, varying from 0.27 to 0.49,
depending on the classification system applied.22–24
In this study, dichotomisation of nuclear grade as
non-high versus high was more reproducible and
thus more robust than dichotomisation as low versus
non-low. Pathologists seem to have more difficulties
with discerning low grade from intermediate grade
than in discerning intermediate grade from high
grade, which confirms previous findings.25 By anal-
ogy with the two-tier system of low-grade squamous
intraepithelial lesions and high-grade squamous
intraepithelial lesions that replaced the three-tier sys-
tem of cervical intraepithelial neoplasia,26 it may be
appropriate to also dichotomise nuclear atypia in
DCIS. Two-tier grading systems have also replaced
three-tier grading systems in other organ systems,
such as the gastrointestinal tract.27 In these different
settings, better agreement among pathologists was
obtained by implementing two-tier grading of dyspla-
sia. Moreover, genomic and molecular studies have
provided evidence for a low-grade pathway and a
high-grade pathway in breast cancer development.28–30
Interestingly, two-tier morphological grading of DCIS
is corroborated by gene expression profiles, as molecu-
lar grading indicated a binary grading scheme for
DCIS.31 Unfortunately, it is impossible to investigate
the interaction of features with one another, as all
histopathological features are present (or absent) in
one lesion. For instance, it is known that high-grade
DCIS more often presents with necrosis, but it is impos-
sible to investigate whether there is a true correlation
or whether pathologists tend to assign a higher
nuclear grade to DCIS with necrosis.
Comparison of median kappa values identified cut-
offs with the lowest interobserver variability for the
presence of necrosis, myxoid stromal changes, and
stromal inflammation. Assessment of necrosis was
most reliable with dichotomisation as no or single
cell-necrosis versus focal or extensive necrosis. Previ-
ous studies provided contradictory evidence on the
prognostic value of necrosis in DCIS, but methods of
assessment differed.9,32–34 It would be interesting to
re-evaluate the prognostic potential of necrosis in a
large DCIS cohort on the basis of the definition used
in this study, as we have shown that this feature is
assessed most reproducibly. Similarly, it would be
worthwhile investigating the prognostic potential of
dichotomous assessment of stromal inflammation (i.e.
absent to mild inflammation versus moderate to
extensive inflammation according to the aforemen-
tioned definitions), as the currently available reports
provide contradictory evidence on the prognostic
value of so-called tumour-infiltrating lymphocytes in
DCIS.9,35–37 Likewise, myxoid changes in the periduc-
tal stroma cannot be overlooked. We previously
reported an association between myxoid stromal
changes and recurrence rates in DCIS patients.10
Here, we have determined a robust cut-off of 33% of
ducts surrounded by myxoid changes, and we now
aim to further explore the relationship between
dichotomised periductal stromal changes and out-
come in an independent cohort of DCIS patients. In
addition, we aim to investigate whether upfront
dichotomous assessment results in similar interob-
server concordance as post-hoc dichotomisation.
Most studies on interobserver variability among
pathologists have focused on the differentiation
between atypical ductal hyperplasia (ADH), DCIS, and
invasive cancer,38–40 but only a few studies have
been performed on agreement regarding histopatho-
logical features within DCIS, mainly focusing on
nuclear grade and architectural patterns.41–43 Here,
we show that dichotomous histopathological assess-
ment results in substantial interobserver concordance
but depends on the chosen cut-off. We advocate the
investigation of interobserver variability before exami-
nation of the prognostic potential of a particular trait,
because prognostic markers are practically useless
when they are not reproducible. In conclusion, it
might be worthwhile considering new DCIS grading
systems or prognostic indexes, based on two-tier
assessment of several histopathological features. A
potential disadvantage of two-tier assessment is the
loss of information that might be clinically relevant,
but we assume that two-tier assessment will be most
robust when used in daily practice. First and fore-
most, this requires further investigation of the prog-
nostic value of each dichotomously assessed
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
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histopathological feature separately, which was
beyond the scope of this study.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Cohen’s kappa values for each duo of
pathologists, assessing solid growth of DCIS as a two-
tier feature, i.e. predominantly solid versus predomi-
nantly non-solid.
Table S2. Cohen’s kappa values for each duo of
pathologists, assessing the presence of necrosis as a
two-tier feature, i.e. no necrosis versus any amount of
necrosis (either single-cell, focal or extensive necrosis).
Table S3. Cohen’s kappa values for each duo of
pathologists, assessing the presence of necrosis as a
two-tier feature, i.e. no necrosis or single-cell necrosis
versus focal necrosis or extensive necrosis.
Table S4. Cohen’s kappa values for each duo of
pathologists, assessing the presence of necrosis as a
two-tier feature, i.e. non-extensive necrosis (either no
necrosis or single-cell necrosis or focal necrosis) versus
extensive necrosis.
Table S5. Cohen’s kappa values for each duo of
pathologists, assessing intraductal calcifications as a
two-tier feature, i.e. absent versus present.
Table S6. Cohen’s kappa values for each duo of
pathologists, assessing the presence or absence of apoc-
rine differentiation as a two-tier feature.
Table S7. Cohen’s kappa values for each duo of
pathologists, assessing periductal stromal changes as a
two-tier feature, i.e. <1% periductal myxoid stroma
versus ≥1% periductal myxoid stroma.
Table S8. Cohen’s kappa values for each duo of
pathologists, assessing periductal stromal changes as a
two-tier feature, i.e. <33% of ducts surrounded by
myxoid stroma versus ≥33% of ducts surrounded by
myxoid stroma.
Table S9. Cohen’s kappa values for each duo of
pathologists, assessing periductal stromal changes as a
two-tier feature, i.e. <66% periductal myxoid stroma
versus ≥66% periductal myxoid stroma.
Table S10. Cohen’s kappa values for each duo of
pathologists, assessing stromal inflammation as a two-
tier feature, i.e. no periductal stromal inflammation
versus any periductal stromal inflammation (either
mild, moderate, or extensive).
Table S11. Cohen’s kappa values for each duo of
pathologists, assessing periductal stromal inflamma-
tion as a two-tier feature, i.e. absent or mild stromal
inflammation versus moderate or extensive stromal
inflammation.
Table S12. Cohen’s kappa values for each duo of
pathologists, assessing stromal inflammation as a two-
tier feature, i.e. non-extensive periductal stromal
inflammation (no inflammation, or mild or moderate
inflammation) versus extensive periductal stromal
inflammation.
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